Cargando…

Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor

The histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) synergizes the cytotoxic effect of doxorubicin (Dox) and anti-HER2 on mammary carcinoma cells while protecting normal cells against their insults. This study investigated the concomitant changes occurring in heart ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarasenko, Nataly, Cutts, Suzanne M., Phillips, Don R., Inbal, Aida, Nudelman, Abraham, Kessler-Icekson, Gania, Rephaeli, Ada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3285631/
https://www.ncbi.nlm.nih.gov/pubmed/22384017
http://dx.doi.org/10.1371/journal.pone.0031393
_version_ 1782224496387686400
author Tarasenko, Nataly
Cutts, Suzanne M.
Phillips, Don R.
Inbal, Aida
Nudelman, Abraham
Kessler-Icekson, Gania
Rephaeli, Ada
author_facet Tarasenko, Nataly
Cutts, Suzanne M.
Phillips, Don R.
Inbal, Aida
Nudelman, Abraham
Kessler-Icekson, Gania
Rephaeli, Ada
author_sort Tarasenko, Nataly
collection PubMed
description The histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) synergizes the cytotoxic effect of doxorubicin (Dox) and anti-HER2 on mammary carcinoma cells while protecting normal cells against their insults. This study investigated the concomitant changes occurring in heart tissue and tumors of mice bearing a subcutaneous 4T1 mammary tumor following treatment with AN-7, Dox, or their combination. Dox or AN-7 alone led to inhibition of both tumor growth and lung metastases, whereas their combination significantly increased their anticancer efficacy and attenuated Dox- toxicity. Molecular analysis revealed that treatment with Dox, AN-7, and to a greater degree, AN-7 together with Dox increased tumor levels of γH2AX, the marker for DNA double-strand breaks and decreased the expression of Rad51, a protein needed for DNA repair. These events culminated in increased apoptosis, manifested by the appearance of cytochrome-c in the cytosol. In the myocardium, Dox-induced cardiomyopathy was associated with an increase in γH2AX expression and a reduction in Rad51 and MRE11 expression and increased apoptosis. The addition of AN-7 to the Dox treatment protected the heart from Dox insults as was manifested by a decrease in γH2AX levels, an increase in Rad51 and MRE11 expression, and a diminution of cytochrome-c release. Tumor fibrosis was high in untreated mice but diminished in Dox- and AN-7-treated mice and was almost abrogated in AN-7+Dox-treated mice. By contrast, in the myocardium, Dox alone induced a dramatic increase in fibrosis, and AN7+Dox attenuated it. The high expression levels of c-Kit, Ki-67, c-Myc, lo-FGF, and VEGF in 4T1 tumors were significantly reduced by Dox or AN-7 and further attenuated by AN-7+Dox. In the myocardium, Dox suppressed these markers, whereas AN-7+Dox restored their expression. In conclusion, the combination of AN-7 and Dox results in two beneficial effects, improved anticancer efficacy and cardioprotection.
format Online
Article
Text
id pubmed-3285631
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-32856312012-03-01 Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor Tarasenko, Nataly Cutts, Suzanne M. Phillips, Don R. Inbal, Aida Nudelman, Abraham Kessler-Icekson, Gania Rephaeli, Ada PLoS One Research Article The histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) synergizes the cytotoxic effect of doxorubicin (Dox) and anti-HER2 on mammary carcinoma cells while protecting normal cells against their insults. This study investigated the concomitant changes occurring in heart tissue and tumors of mice bearing a subcutaneous 4T1 mammary tumor following treatment with AN-7, Dox, or their combination. Dox or AN-7 alone led to inhibition of both tumor growth and lung metastases, whereas their combination significantly increased their anticancer efficacy and attenuated Dox- toxicity. Molecular analysis revealed that treatment with Dox, AN-7, and to a greater degree, AN-7 together with Dox increased tumor levels of γH2AX, the marker for DNA double-strand breaks and decreased the expression of Rad51, a protein needed for DNA repair. These events culminated in increased apoptosis, manifested by the appearance of cytochrome-c in the cytosol. In the myocardium, Dox-induced cardiomyopathy was associated with an increase in γH2AX expression and a reduction in Rad51 and MRE11 expression and increased apoptosis. The addition of AN-7 to the Dox treatment protected the heart from Dox insults as was manifested by a decrease in γH2AX levels, an increase in Rad51 and MRE11 expression, and a diminution of cytochrome-c release. Tumor fibrosis was high in untreated mice but diminished in Dox- and AN-7-treated mice and was almost abrogated in AN-7+Dox-treated mice. By contrast, in the myocardium, Dox alone induced a dramatic increase in fibrosis, and AN7+Dox attenuated it. The high expression levels of c-Kit, Ki-67, c-Myc, lo-FGF, and VEGF in 4T1 tumors were significantly reduced by Dox or AN-7 and further attenuated by AN-7+Dox. In the myocardium, Dox suppressed these markers, whereas AN-7+Dox restored their expression. In conclusion, the combination of AN-7 and Dox results in two beneficial effects, improved anticancer efficacy and cardioprotection. Public Library of Science 2012-02-23 /pmc/articles/PMC3285631/ /pubmed/22384017 http://dx.doi.org/10.1371/journal.pone.0031393 Text en Tarasenko et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Tarasenko, Nataly
Cutts, Suzanne M.
Phillips, Don R.
Inbal, Aida
Nudelman, Abraham
Kessler-Icekson, Gania
Rephaeli, Ada
Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor
title Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor
title_full Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor
title_fullStr Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor
title_full_unstemmed Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor
title_short Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor
title_sort disparate impact of butyroyloxymethyl diethylphosphate (an-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3285631/
https://www.ncbi.nlm.nih.gov/pubmed/22384017
http://dx.doi.org/10.1371/journal.pone.0031393
work_keys_str_mv AT tarasenkonataly disparateimpactofbutyroyloxymethyldiethylphosphatean7ahistonedeacetylaseinhibitoranddoxorubicininmicebearingamammarytumor
AT cuttssuzannem disparateimpactofbutyroyloxymethyldiethylphosphatean7ahistonedeacetylaseinhibitoranddoxorubicininmicebearingamammarytumor
AT phillipsdonr disparateimpactofbutyroyloxymethyldiethylphosphatean7ahistonedeacetylaseinhibitoranddoxorubicininmicebearingamammarytumor
AT inbalaida disparateimpactofbutyroyloxymethyldiethylphosphatean7ahistonedeacetylaseinhibitoranddoxorubicininmicebearingamammarytumor
AT nudelmanabraham disparateimpactofbutyroyloxymethyldiethylphosphatean7ahistonedeacetylaseinhibitoranddoxorubicininmicebearingamammarytumor
AT kesslericeksongania disparateimpactofbutyroyloxymethyldiethylphosphatean7ahistonedeacetylaseinhibitoranddoxorubicininmicebearingamammarytumor
AT rephaeliada disparateimpactofbutyroyloxymethyldiethylphosphatean7ahistonedeacetylaseinhibitoranddoxorubicininmicebearingamammarytumor